Prevention Innovation Program III (PIP) (R01)

Funding Opportunity Number: RFA-AI-16-025
Opportunity Category: Discretionary
Funding Instrument Type: Grant
Category of Funding Activity: Health
CFDA Number: 93.855
Eligible Applicants State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Agency Name: HHS-NIH11
Closing Date: Aug 03, 2016
Award Ceiling: $400,000
Expected Number of Awards:
Creation Date: Mar 29, 2016
Funding Opportunity Description: The Prevention Innovation Program III (PIP) encourages research applications in Non-vaccine Biomedical Prevention (nBP) research. The PIP is intended to support high-risk/innovative research and development efforts to establish and maintain a sustainable pipeline for the prevention of HIV acquisition/transmission. The PIP will support: 1) discovery and development of novel and under-explored nBP candidates/strategies, 2) discovery and development of nBP drug delivery systems (DDS), 3) studies of the impact of nBP prevention products and DDS on genital and gastrointestinal (GI) mucosa function, 4) development of emerging technologies to support and facilitate nBP prevention product and DDS discovery and development, 5) development of age appropriate formulation strategies (AFS), and 6) development of Multipurpose Prevention Technologies (MPT) for prevention of HIV acquisition/transmission.



Please enter your comment!
Please enter your name here